ApicHope Pharmaceutical Group (300723.SZ) subsidiary's innovative drug APH03867 tablet clinical trial application has been approved.

ApicHope Pharmaceutical Group (300723.SZ) announced that recently, its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Group Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of its self-developed innovative drug, APH03867 tablets, and has obtained the "Notice of Approval for Drug Clinical Trials." Clinical trials will begin shortly. It is reported that APH03867 tablets are a novel oral, non-peptide small molecule URAT1 inhibitor (full name: Urate Transporter 1) developed independently by the company. By inhibiting the activity of URAT1 in the kidneys, it blocks the reabsorption of uric acid in the renal tubules, increasing uric acid excretion and effectively lowering blood uric acid levels. It can be used to improve symptoms of hyperuricemia and gout.